Monoclonal Antibodies

While our cancer vaccines are designed to elicit a cellular immune response, our monoclonal antibodies are designed to selectively seek and destroy cancer cells. Because they are engineered to bind only to cancer-specific antigens, they may also be used to diagnose a wide range of cancers.

All in preclinical development, our monoclonal antibodies were produced using our proprietary Differentiated Immunization for Antigen and Antibody Discovery (DIAAD) discovery technology, which enables the rapid discovery of antigen targets and corresponding monoclonal antibodies for the treatment and diagnosis of cancer and other diseases.